Table 1– Basal characteristics, clinical presentation and microbiological data of pneumococcal pneumonia patients
Presenting with respiratory failurePresenting without respiratory failurep-value
Subjects n615643
Sociodemographic and temporal variables
 Age years62.1355.42<0.001
 Male411/615 (66.9)388/615 (60.4)0.019
 Period of influenza epidemic155/513 (25.2)169/643 (26.3)ns
 Previous pneumococcal vaccination124/513 (24.1)96/561 (17.1)0.015
 Smoking341/607 (56.2)349/631 (55.3)ns
 Heavy alcohol consumption127/605 (21)101/629 (16.1)0.028
Underlying disease
 Chronic lung disease216/607 (35.6)144/631 (22.8)<0.001
 Chronic heart disease140/605 (23.1)76/623 (12.2)<0.001
 Cerebrovascular disease75/605 (12.4)40/623 (6.4)0.001
 HIV infection94/611 (15.4)124/638 (19.4)0.063
 Haematological cancer46/610 (7.5)47/638 (7.4)ns
 Solid cancer84/610 (13.8)68/638 (10.3)0.068
Clinical presentation and outcomes
 Bilateral pneumonia210/614 (34.2)63/643 (9.8)<0.001
 Bilobar or multilobar pneumonia347/614 (58.2)109/643 (17)<0.001
 Septic shock254/609 (41.7)39/638 (6.1)<0.001
 ICU admission234/609 (38.4)27/638 (4.2)<0.001
 PSI ≥4#533/609 (87.6)328/638 (51.4)<0.001
 Mechanical ventilation161/609 (26.1)15/639 (2.3)<0.001
 Length of hospital stay days17.8310.62<0.001
 Empyema120/615 (19.5)120/643 (18.7)ns
 Hospital mortality157/615 (25.5)23/643 (3.5)<0.001
Microbiological data
 Serotype 142/480 (8.8)98/543 (18)<0.001
 Serotype 379/480 (16.5)41/523 (7.6)<0.001
 Serotype 7F27/480 (5.6)45/523 (8.3)0.111
 Serotype 825/480 (5.2)30/523 (5.4)0.467
 Serotype 19A38/480 (7.9)20/523 (3.7)0.004
 Serotype 19F22/480 (4.6)5/523 (0.9)<0.001
 Serotype 23A2/480 (0.4)9/523 (1.7)0.07
 Serotype 23F5/480 (1)16/523 (2.9)0.045
 Penicillin susceptibility600/615 (97.5)633/643 (98.5)ns
 Cephalosporin susceptibility+601/615 (97.7)624/643 (97)ns
  • Data are presented as mean or n/N (%), unless otherwise stated. ICU: intensive care unit; PSI: pneumonia severity index; ns: nonsignificant. #: PSI score ≥4 at the moment of admission to the emergency department; : includes isolates with minimum inhibitory concentration (MIC) ≤2 μg·mL−1; +: includes isolates with MIC ≤1 μg·mL−1.